newsbreast cancerCDK4/6 inhibitors
Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
By MedXY|Mar 12, 2026
The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and h
